American court confirms Atrium's exclusive U.S. rights to the renowned Wobenzym(R) N



    Wobenzym(R) N, which generates more than US$90 million in annual sales
    for Atrium in Europe, holds considerable commercial potential for the
    U.S.

    QUEBEC CITY, Nov. 15 /CNW Telbec/ - Atrium Innovations Inc., "Atrium"
(TSX: ATB), is pleased to announce that following an American court decision,
the Company has received approval to sell its enzyme supplement Wobenzym(R) N
in the United States. Marlyn Nutraceuticals, Inc. "Marlyn", located in
Phoenix, Arizona, has been ordered by the U.S. District Court to immediately
stop using the Wobenzym(R) N trademark and selling products under this name.
    Wobenzym(R) N was initially developed more than 40 years ago by Mucos
Pharma GmbH & Co "Mucos", a company acquired by Atrium in July 2007.          
Wobenzym(R) N is an enzyme-based product well known within the medical
community in Germany and certain Eastern European countries for its numerous
benefits for the health of joints, muscles and tendons as well as for the
immune system. As one of the top selling joint and muscle health products in
these countries, annual sales of Wobenzym(R) N by Mucos currently stand at
over US$90 million.
    "We are very pleased with this court ruling, which will allow us to start
selling Wobenzym(R) N in the United States immediately and with no
restrictions," stated Pierre Fitzgibbon, President and Chief Executive Officer
of Atrium Innovations. "This high-quality product, sold as an enzyme
supplement in the U.S., offers a natural solution to very common conditions
such as joint and muscle discomfort. Through our two American subsidiaries,
Douglas Laboratories and Pure Encapsulations, which serve some 40,000
healthcare professionals in the U.S., we have gained in-depth knowledge of
this market, and this edge will allow us to rapidly commercialize             
Wobenzym(R) N. We also intend to draw on other specialized distribution
networks that offer strong business potential. This decision signifies a major
development for Atrium and will allow the Company to accelerate its growth and
development in the United States."
    For more information on Wobenzym(R) N, please visit our Web site at
www.wobenzym-usa.com

    About Atrium

    Atrium Innovations Inc. is a recognized leading developer, manufacturer
and marketer of science-based products for the cosmetics, pharmaceutical,
chemical and nutrition industries. The Company focuses primarily on growing
segments of the health and personal care markets, which are benefiting from
the trends towards healthy living and the ageing of the population. Atrium
markets a broad portfolio of active ingredients, specialty chemicals and
health and nutrition finished products through its highly specialized sales
and marketing network in more than 50 countries, primarily in North America,
Europe and Asia. Atrium has over 600 employees and operates four manufacturing
facilities. Additional information about Atrium is available on its Web site
at www.atrium-innov.com.

    Cautionary Note and Forward-Looking Statements

    This press release contains certain forward-looking statements with
respect to the Company. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by these forward-looking statements.
The Company considers the assumptions on which these forward-looking
statements are based to be reasonable, but cautions the reader that these
assumptions regarding future events, many of which are beyond its control, may
ultimately prove to be incorrect since they are subject to risks and
uncertainties that affect the Company. For additional information with respect
to these and other factors, see the Company's quarterly and annual filings
with the Canadian securities commissions. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, other than as required
by law.




For further information:

For further information: Investor Relations: John Dempsey,
Vice-President, Finance, and Chief Financial Officer, (418) 652-1116, ext.
287, jdempsey@atrium-innov.com; Media Relations: Frédéric Tremblay, HKDP,
(514) 395-0375, ext. 234, ftremblay@hkdp.qc.ca

Organization Profile

Atrium Innovations Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890